AURX 8-K
Nuo Therapeutics, Inc. (AURX)
8-K
2022-12-05
For: 2022-12-02
View Original
Added on
April 06, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 2, 2022
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
|
of incorporation)
|
File Number)
|
Identification No.)
|
(Address of principal executive offices) (Zip Code)
(346 ) 396-4770
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act: None
|
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.07 Submission of Matters to a Vote of Security Holders.
On December 2, 2022, Nuo Therapeutics, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders. The following matters were considered and voted upon:
|
1.
|
To elect four directors to serve on the Company’s Board of Directors, each to serve until the Company’s next annual meeting of stockholders or until each successor is duly elected and qualified;
|
|
2.
|
To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
|
|
3.
|
To approve, on an advisory basis, the compensation of the Company’s named executive officers;
|
|
4.
|
To approve, on an advisory basis, the frequency of the advisory vote on executive compensation; and
|
|
5.
|
To ratify and approve the Company’s 2016 Omnibus Incentive Compensation Plan, as amended.
|
The results of the vote were as follows:
|
1.
|
Election of Directors
|
For
|
Withheld
|
Broker Non-Votes
|
|
|
David E. Jorden
|
26,699,444
|
3,323
|
996,251
|
||
|
C. Eric Winzer
|
26,198,490
|
504,277
|
996,251
|
||
|
Scott M. Pittman
|
26,199,444
|
503,323
|
996,251
|
||
|
Paul D. Mintz
|
26,199,444
|
503,323
|
996,251
|
||
|
For
|
Withheld
|
Abstain
|
|||
|
2.
|
To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022
|
27,697,944
|
1,074
|
0
|
|
|
For
|
Withheld
|
Abstain
|
|||
|
3.
|
To approve, on an advisory basis, the compensation of the Company’s named executive officers
|
26,692,397
|
5,370
|
5,000
|
|
|
One Year
|
Two Years
|
Three Years
|
Abstain
|
||
|
4.
|
To approve, on an advisory basis, the frequency of the advisory vote on executive compensation
|
2,389,764
|
37,874
|
23,767,794
|
507,335
|
|
For
|
Withheld
|
Abstain
|
|||
|
5.
|
To ratify and approve the Company’s 2016 Omnibus Incentive Compensation Plan, as amended
|
26,188,825
|
7,988
|
505,954
|
In light of the voting results on Proposal 4 the Board of Directors has determined that the Company will include an advisory vote on executive compensation in the Company’s proxy materials every three years until the next required advisory vote on the frequency of future advisory votes on executive compensation, which will occur no later than the Company’s 2028 Annual Meeting of Stockholders.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Nuo Therapeutics, Inc.
|
|||
|
By:
|
/s/ David E. Jorden
|
||
|
David E. Jorden
|
|||
|
Chief Executive and Chief Financial Officer
|
|||
Date: December 5, 2022